Ann Clin Case Rep | Volume 7, Issue 1 | Case Report | Open Access
Derasse M1*, D’Haene N2, Berghmans T1 and Grigoriu B1
1Department of Thoracic Oncology, Jules Bordet Institute, Belgium
2Department of Pathology, Erasme Hospital, Belgium
*Correspondance to: Marion DerasseFulltext PDF
Introduction: Liquid biopsy is increasingly used in management of Non-Small Cell Lung Cancer (NSCLC), especially when tissue availability tumor is limited. This especially true in the context of Leptomeningeal metastases. The circulating cell-free DNA from plasma or cerebrospinal fluid may provide genetic material needed for the diagnosis and management of patients with LM progression. Case Report: We present the case of a 38-year-old Chinese female with a stage IVb NSCLC Epidermal Growth Factor Receptor (EGFR)- mutant with LM progression under Afatinib. A Droplet Digital PCR showed the presence of an EGFR exon 19 deletion and the T790M resistance mutation on both on plasma and CSF. Osimertinib resulted a rapid improvement in the clinical and neurological condition. Conclusion: Analysis of cfDNA can provide valuable data for management of EGFR-mutant NSCLC progression under tyrosine kinase inhibitors.
Derasse M, D’Haene N, Berghmans T, Grigoriu B. Liquid Biopsy for Detection of T790M Mutation in Patient with EGFR-Mutant Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Case Report. Ann Clin Case Rep. 2022; 7: 2361.